Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business strategies and performance metrics. Group 1: Company Performance - In 2024, the company achieved total revenue of 1.349 billion yuan, representing a year-on-year growth of 16.93% [6] - The net profit attributable to shareholders was 113 million yuan, an increase of 11.54% year-on-year [6] - The company's proprietary drug business generated 283 million yuan in revenue, marking a 44.31% increase compared to the previous year [6][7] Group 2: Business Strategy - The company is focused on a management-style medical strategy, which has led to a revenue growth of 25%-30% in its pharmaceutical and medical services sectors [4] - The company aims to enhance its digital health management services, covering the entire patient lifecycle, to improve drug sales and patient compliance [4][7] - The company plans to optimize its liver disease patient management system in response to the "Healthy China 2030" initiative [4] Group 3: Market Position and Future Outlook - The domestic market accounted for 36.72% of revenue, while the international market contributed 63.28% in 2024 [4] - The company is committed to becoming a professional and international management-style medical group, focusing on liver cancer screening and management [4][7] - The company anticipates that the market for its products will enter a rapid growth phase following the approval of the MASH indication by the FDA [4][8] Group 4: Product and Service Development - The company has developed a full-cycle management solution for liver disease, integrating screening, diagnosis, and treatment [4][7] - The FibroScan Go and box products have been installed in 651 units globally, becoming new revenue growth points for the company [7] - The company is enhancing its marketing strategies for its proprietary drugs and expanding its e-commerce channels to sustain high growth rates [6][7]

Group 1: Company Performance and Financials - In 2024, the company achieved total revenue of CNY 1.349 billion, a year-on-year increase of 16.93% [10] - The net profit attributable to shareholders was CNY 113 million, up 11.54% year-on-year [10] - The revenue contribution from the equipment and technology segment was approximately 68%, while the pharmaceutical segment contributed about 28%, and medical services and others accounted for around 4% [8] Group 2: Product and Market Strategy - The company’s self-owned pharmaceutical business generated revenue of CNY 283 million in 2024, reflecting a growth of 44.31% [7] - The sales channels for pharmaceuticals, particularly e-commerce, showed significant growth, with increases of 87.44% and 145.37% respectively [10] - The company aims to enhance its market penetration globally, focusing on management-style medical services and improving patient management [10] Group 3: Future Outlook and Strategic Initiatives - The company plans to submit its products for FDA approval in Q1 2026, with a focus on improving financial conditions through increased commercial activities [2] - The management strategy includes a dual approach of consolidating traditional sales channels while developing digital health management services [8] - The company is committed to optimizing the liver disease patient management system and enhancing early screening strategies [12] Group 4: Risk Management and Cost Control - The company has established a risk assessment management system to identify and respond to potential risks [5] - In 2024, the pharmaceutical gross margin increased to 47.71%, a rise of 9.46 percentage points year-on-year [15] - Measures to control costs include managing the procurement of key raw materials like Cordyceps and ensuring operational efficiency [16]